Several other PROTACs targeting FLT3 alone have also been shown to degrade the kinase, reduce oncogenic FLT3 ITD signalling, and decrease cell proliferation in vitro, as well as exhibiting anti-tumour activity in vivo [21,31,87,90,91]. Here, FLT3 is linked to neoplasm.